GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
The acquisition is set to give GSK ownership of three drug candidates for lung cancer, two of which are under FDA review for approval this year.
J.M. Smucker Expects Sales to Fall This Year
J.M. Smucker guided for sales to decline in the coming year as it leans away from price increases, looking instead to drive volume growth in key areas and improve profitability.
BP Names Heads of Newly-Created Segments as Part of Simplification Push
GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
Anthropic Releases New 'Mythos-Class' Model to General Public With Guardrails
Britain's GSK has announced its $10.6 billion acquisition of US-based cancer-focused biopharma firm Nuvalent, paying a 40%…
GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
GSK buys US biopharma company Nuvalent for $10.6B
GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
GSK Boosts Cancer Portfolio, Acquires Nuvalent for $10.6 Billion
Nuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal
GSK acquires Nuvalent for $10.6 billion to rebuild its oncology business
GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B
GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent
UK pharma giant GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
Pharmalittle: We're reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
$10. 6 billion deal: GSK to buy US cancer specialist Nuvalent
